The US Food and Drug Administration (FDA) has authorised the use of Cook Medical’s Flourish Pediatric Esophageal Atresia Anastomosis device for the treatment of esophageal atresia in infants up to one year old.

Esophageal atresia is a birth defect observed in babies and is characterised by a gap in the esophagus.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Flourish device closes the gap by using magnets to pull the upper and lower esophagus together.

During the procedure, two catheters are inserted separately through the mouth and the stomach.

The magnetic ends of these catheters attract each other, pulling the ends of the esophagus together, over several days.

See Also:

The infant can be fed through the mouth, following the removal of the catheters.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"This new device provides a non-surgical option for doctors to treat esophageal atresia in babies born with this condition."

The device cannot be used in infants with tracheoesophageal fistula, which is an abnormal connection between the esophagus and the windpipe (trachea).

FDA Centre for Devices and Radiological Health Device Evaluation office acting director William Maisel said: “This new device provides a non-surgical option for doctors to treat esophageal atresia in babies born with this condition.

“But it is only intended for infants who do not have a tracheoesophageal fistula or who have had the fistula repaired in a prior surgery.”

The FDA authorisation is based on the safety data obtained from the evaluation of the Flourish device in 16 patients.

While joining of their esophagus was observed within three to ten days, with no gap, 13 of the 16 infants developed a complication that required a balloon dilation procedure and/or a stent for repair.